0102030405
CAS No 941685-37-6 S-RUXOLITINIB Pharmaceutical Intermediates
02
OVERVIEW
S-ruxolitinib is a novel pharmaceutical compound that has attracted attention for its role in the treatment of myelofibrosis and other related diseases.
This drug is specifically designed to inhibit the JAK1 and JAK2 enzymes, which play critical roles in signaling pathways in various blood diseases.
As a product of our integrated manufacturing and trading facilities, S-ruxolitinib embodies our commitment to quality, innovation and customer satisfaction.
By targeting these pathways, S-ruxolitinib helps relieve symptoms and improve quality of life in patients with myelofibrosis.
This drug is specifically designed to inhibit the JAK1 and JAK2 enzymes, which play critical roles in signaling pathways in various blood diseases.
As a product of our integrated manufacturing and trading facilities, S-ruxolitinib embodies our commitment to quality, innovation and customer satisfaction.
By targeting these pathways, S-ruxolitinib helps relieve symptoms and improve quality of life in patients with myelofibrosis.
02
Physical and chemical properties
- Molecular Weight: 306.36g/mol
- Solubility: It is soluble in organic solvents such as dimethyl sulfoxide (DMSO) and methanol, but has limited solubility in water. This property is advantageous in certain pharmaceutical formulations.
- STABILITY: The compound exhibits good stability under standard storage conditions, ensuring a longer shelf life and maintaining its therapeutic effects.
These properties not only enhance the performance of S-Ruxolitinib in pharmaceutical formulations, but also enhance its versatility in various applications in the treatment of hematological disorders.
- Solubility: It is soluble in organic solvents such as dimethyl sulfoxide (DMSO) and methanol, but has limited solubility in water. This property is advantageous in certain pharmaceutical formulations.
- STABILITY: The compound exhibits good stability under standard storage conditions, ensuring a longer shelf life and maintaining its therapeutic effects.
These properties not only enhance the performance of S-Ruxolitinib in pharmaceutical formulations, but also enhance its versatility in various applications in the treatment of hematological disorders.
1. Targeted therapy: S-Ruxolitinib specifically targets the JAK1 and JAK2 enzymes, providing a targeted treatment that can enhance the therapeutic effect of myelofibrosis and other related diseases.
2. Symptom relief: Clinical studies have shown that S-Ruxolitinib significantly reduces splenomegaly and relieves systemic symptoms, improving patients’ overall quality of life.
3. Convenient dosing regimen: S-Ruxolitinib is typically administered orally, providing a convenient dosing schedule that improves patient compliance and overall treatment experience.
4. Proven Safety: S-ruxolitinib has an adequate safety profile and is a reliable ingredient in the treatment of myelofibrosis. Its use is supported by numerous research and clinical studies, ensuring it meets safety and effectiveness standards.
5. Cost-effectiveness: As a product of our integrated factory, S-ruxolitinib is highly competitively priced without compromising on quality. This cost-effectiveness makes it an attractive option for pharmaceutical companies and healthcare providers.
6. Sustainability: We are committed to sustainable manufacturing practices to ensure that the production of S-Ruxolitinib has minimal environmental impact. We prioritize environmentally friendly processes and materials to meet the growing demand for sustainable pharmaceutical solutions.
2. Symptom relief: Clinical studies have shown that S-Ruxolitinib significantly reduces splenomegaly and relieves systemic symptoms, improving patients’ overall quality of life.
3. Convenient dosing regimen: S-Ruxolitinib is typically administered orally, providing a convenient dosing schedule that improves patient compliance and overall treatment experience.
4. Proven Safety: S-ruxolitinib has an adequate safety profile and is a reliable ingredient in the treatment of myelofibrosis. Its use is supported by numerous research and clinical studies, ensuring it meets safety and effectiveness standards.
5. Cost-effectiveness: As a product of our integrated factory, S-ruxolitinib is highly competitively priced without compromising on quality. This cost-effectiveness makes it an attractive option for pharmaceutical companies and healthcare providers.
6. Sustainability: We are committed to sustainable manufacturing practices to ensure that the production of S-Ruxolitinib has minimal environmental impact. We prioritize environmentally friendly processes and materials to meet the growing demand for sustainable pharmaceutical solutions.
In conclusion, due to its innovative mechanism of action, enhanced efficacy, and strong safety profile, S-ruxolitinib has become the first choice for the treatment of myelofibrosis and other hematological diseases.
With S-ruxolitinib, you can rest assured that you are choosing a reliable and effective solution for your pharmaceutical needs.
As a factory integrating production and trading, we are committed to providing customers with high-quality products that meet the highest industry standards.
Partner with us today to experience the benefits of S-ruxolitinib and enhance your drug offering for the treatment of hematological disorders.
With S-ruxolitinib, you can rest assured that you are choosing a reliable and effective solution for your pharmaceutical needs.
As a factory integrating production and trading, we are committed to providing customers with high-quality products that meet the highest industry standards.
Partner with us today to experience the benefits of S-ruxolitinib and enhance your drug offering for the treatment of hematological disorders.